Stock Analysis on Net

Johnson & Johnson (NYSE:JNJ)

$24.99

Analysis of Profitability Ratios
Quarterly Data

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Profitability Ratios (Summary)

Johnson & Johnson, profitability ratios (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Return on Sales
Gross profit margin
Operating profit margin
Net profit margin
Return on Investment
Return on equity (ROE)
Return on assets (ROA)

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).


The profitability analysis reveals a divergence between core operational stability and bottom-line volatility. While gross and operating margins remained relatively consistent, the net profit margin, return on equity, and return on assets exhibited significant fluctuations, characterized by extreme peaks and subsequent sharp corrections.

Gross Profit Margin
Performance remained highly stable, fluctuating within a narrow band between 67.26% and 69.20%. A gradual improvement peaked in March 2024, followed by a marginal contraction that brought the margin back to 67.82% by March 2026.
Operating Profit Margin
Operating efficiency showed a moderate upward trajectory over the analyzed period. Initial values fluctuated between 23% and 25% through 2022 and 2023. Despite a temporary dip to 23.42% in December 2024, the margin recovered to a peak of 26.85% in December 2025, ending the period at 26.39%.
Net Profit Margin
Significant volatility is observed in the net profit margin. A contraction to 13.77% in April 2023 preceded an anomalous surge that peaked at 44.92% in March 2024. This was followed by a sharp correction to 15.84% by September 2024, before the margin stabilized between 21.83% and 28.46% throughout 2025 and early 2026.
Return on Equity (ROE)
ROE mirrored the volatility of the net profit margin. After dipping to 17.37% in July 2023, the ratio spiked to a high of 54.95% in March 2024. A subsequent rapid decline led to a low of 19.68% in September 2024, followed by a recovery to a peak of 32.87% in December 2025 and a final value of 25.92% in March 2026.
Return on Assets (ROA)
ROA followed a similar pattern of expansion and contraction. From a low of 6.49% in April 2023, the ratio surged to 22.37% by March 2024. This was followed by a sharp decline to 7.81% in September 2024, before normalizing and fluctuating between 10.47% and 13.46% through the remainder of the period.

The data suggests that while the fundamental cost of goods sold and operating expenses remained controlled, the net results were heavily influenced by non-recurring items or extraordinary gains and losses, particularly between late 2023 and mid-2024.


Return on Sales


Return on Investment


Gross Profit Margin

Johnson & Johnson, gross profit margin calculation (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Gross profit
Sales to customers
Profitability Ratio
Gross profit margin1
Benchmarks
Gross Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Gross profit margin = 100 × (Gross profitQ1 2026 + Gross profitQ4 2025 + Gross profitQ3 2025 + Gross profitQ2 2025) ÷ (Sales to customersQ1 2026 + Sales to customersQ4 2025 + Sales to customersQ3 2025 + Sales to customersQ2 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The gross profit margin exhibits a period of moderate volatility characterized by an initial decline, a subsequent expansion phase, and a final stage of stabilization. The margin fluctuated within a relatively tight range, reaching a minimum of 67.26% in December 2022 and peaking at 69.20% in March 2024.

Initial Margin Compression (2022)
A consistent downward trend is observed throughout 2022, with the gross profit margin declining from 67.97% in April to 67.26% by December. This compression occurred despite sales to customers remaining relatively stable, ranging between 23.4 billion and 24.0 billion US dollars.
Expansion and Peak Performance (2023 – Early 2024)
Beginning in April 2023, a recovery phase emerged. Notably, the gross profit margin expanded steadily from 67.34% in April 2023 to its peak of 69.20% in March 2024. This improvement in efficiency is particularly significant as it occurred while sales to customers were initially lower than 2022 levels, suggesting an optimization of cost of goods sold or a shift toward higher-margin product mixes.
Stabilization and Normalization (Mid 2024 – March 2026)
Following the March 2024 peak, the margin entered a phase of stabilization, hovering around 69% for three consecutive quarters before declining to 68.30% in December 2024. From March 2025 through March 2026, the margin normalized, fluctuating within a narrow band between 67.82% and 68.08%. During this final period, sales volumes recovered to previous highs, peaking at 24.56 billion US dollars in September 2025, though this growth in revenue did not translate into further margin expansion.

Operating Profit Margin

Johnson & Johnson, operating profit margin calculation (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Operating earnings
Sales to customers
Profitability Ratio
Operating profit margin1
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Operating profit margin = 100 × (Operating earningsQ1 2026 + Operating earningsQ4 2025 + Operating earningsQ3 2025 + Operating earningsQ2 2025) ÷ (Sales to customersQ1 2026 + Sales to customersQ4 2025 + Sales to customersQ3 2025 + Sales to customersQ2 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The operating profit margin exhibited a fluctuating but generally ascending trajectory over the period from April 2022 to March 2026. While the margin remained primarily within the 23% to 27% range, the data reveals distinct phases of expansion, contraction, and recovery, reflecting varying levels of operational efficiency relative to sales volume.

Initial Stability and Expansion (April 2022 – July 2023)
During the first fifteen months, the operating profit margin showed a steady upward trend, rising from 23.76% to a peak of 25.61%. This growth was achieved despite sales to customers remaining relatively flat, suggesting an improvement in internal cost controls or a favorable shift in product mix.
Operational Contraction and Volatility (October 2023 – December 2024)
A period of margin compression occurred starting in late 2023. The margin declined from 25.55% in October 2023 to a trough of 23.42% by December 2024. This downturn was characterized by significant volatility in operating earnings, which dropped to a low of 3,582 million USD in December 2024, even as sales figures remained resilient and slightly increased to 22,520 million USD.
Recovery and Peak Performance (March 2025 – March 2026)
A robust recovery is observed throughout 2025, with the operating profit margin accelerating to its highest point of 26.85% in December 2025. This expansion was driven by a substantial increase in operating earnings, which peaked at 7,033 million USD in September 2025. The period concluded with a slight correction to 26.39% in March 2026, maintaining a baseline significantly higher than the 2022 levels.

Overall, the relationship between operating earnings and sales indicates that the fluctuations in profit margins were driven more by earnings volatility than by changes in top-line revenue. The trend concludes with the company operating at a higher efficiency level than at the start of the analyzed period.


Net Profit Margin

Johnson & Johnson, net profit margin calculation (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Net earnings (loss)
Sales to customers
Profitability Ratio
Net profit margin1
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Net profit margin = 100 × (Net earnings (loss)Q1 2026 + Net earnings (loss)Q4 2025 + Net earnings (loss)Q3 2025 + Net earnings (loss)Q2 2025) ÷ (Sales to customersQ1 2026 + Sales to customersQ4 2025 + Sales to customersQ3 2025 + Sales to customersQ2 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The net profit margin exhibits significant volatility over the analyzed period, characterized by a baseline of approximately 19% to 21%, a severe short-term contraction, an extraordinary spike in profitability, and a subsequent period of stabilization at a higher margin floor.

Initial Stability and Contraction
Between April 2022 and December 2022, the net profit margin remained relatively stable, fluctuating within a narrow range between 18.90% and 20.90%. This stability was disrupted in April 2023, where the margin dropped sharply to 13.77%, coinciding with a net loss of 68 million US dollars, marking the only period of negative earnings in the sequence.
Period of Extraordinary Profitability
A substantial upward surge in profitability is observed starting in October 2023, with the net profit margin climbing to 39.58% and peaking at 44.92% in March 2024. This trend is driven by a massive increase in net earnings, specifically the peak of 26,028 million US dollars in October 2023, which occurred despite sales to customers remaining relatively stagnant near 21,351 million US dollars. This indicates the influence of non-operating gains or one-time financial events rather than organic revenue growth.
Correction and Normalization
Following the peak, a sharp correction occurred between September 2024 and December 2024, with margins receding to 16.74% and 15.84%, respectively. However, from January 2025 through December 2025, a steady recovery trend is evident, with the margin incrementally rising from 24.41% to a high of 28.46%. The period concludes with a moderation to 21.83% in March 2026, suggesting a return to a normalized, albeit improved, profitability level compared to the 2022 baseline.

Return on Equity (ROE)

Johnson & Johnson, ROE calculation (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Net earnings (loss)
Total Johnson & Johnson shareholders’ equity
Profitability Ratio
ROE1
Benchmarks
ROE, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
ROE = 100 × (Net earnings (loss)Q1 2026 + Net earnings (loss)Q4 2025 + Net earnings (loss)Q3 2025 + Net earnings (loss)Q2 2025) ÷ Total Johnson & Johnson shareholders’ equity
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


The Return on Equity (ROE) demonstrates substantial volatility between April 2022 and March 2026, characterized by a period of extreme elevation followed by a stabilization phase. The fluctuations in ROE are predominantly attributed to significant variances in quarterly net earnings, as shareholders' equity remained relatively stable throughout the period.

Earnings Impact on Profitability
A notable contraction in ROE occurred in April 2023, dropping to 17.95%, which coincided with a reported net loss of 68 million dollars. Conversely, an exceptional peak in ROE was observed between October 2023 and June 2024, with values reaching a maximum of 54.95% in March 2024. This surge was driven by a substantial increase in net earnings, most notably the 26.028 billion dollars recorded in October 2023.
Equity Base Stability
Total shareholders' equity maintained a consistent range, generally fluctuating between 68.774 billion dollars and 81.544 billion dollars. The relative stability of the equity base suggests that the dramatic swings in ROE were not the result of capital restructuring or significant buybacks, but were instead the direct consequence of operational or non-operational earnings volatility.
Recent Trend Analysis
Following a sharp decline in late 2024, where ROE fell to 19.68% by December, a recovery trend emerged throughout 2025. ROE climbed steadily to reach 32.87% by December 2025, supported by an increase in both net earnings and total equity. A subsequent moderate decline to 25.92% was observed in March 2026, returning the ratio toward historical averages seen in 2022.

Return on Assets (ROA)

Johnson & Johnson, ROA calculation (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Net earnings (loss)
Total assets
Profitability Ratio
ROA1
Benchmarks
ROA, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
ROA = 100 × (Net earnings (loss)Q1 2026 + Net earnings (loss)Q4 2025 + Net earnings (loss)Q3 2025 + Net earnings (loss)Q2 2025) ÷ Total assets
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


The Return on Assets (ROA) exhibits significant volatility throughout the analyzed period, characterized by an extreme mid-term spike followed by a phase of gradual stabilization. While the ratio initially fluctuated within a narrow range of 9.57% to 11.12% during 2022, it experienced substantial variances in 2023 and 2024 before converging toward a baseline above 10% by early 2026.

Earnings Volatility and Impact on ROA
A sharp contraction in ROA occurred in April 2023, falling to 6.49%, which directly corresponds to a period of negative net earnings totaling -68 million. This decline was followed by an exceptional surge, with ROA peaking at 22.37% in March 2024. This spike was primarily driven by a massive increase in net earnings to 26,028 million in October 2023, representing a significant outlier in the profitability trend.
Asset Base Fluctuations
The asset base demonstrated a notable contraction in late 2023, dropping to 166,061 million in October. The simultaneous occurrence of this asset reduction and the surge in net earnings amplified the ROA peak during the 2023-2024 window. Following this period, total assets entered a consistent growth trajectory, expanding to 200,894 million by March 2026, which exerted downward pressure on the ROA as the asset denominator increased.
Long-term Stability and Recovery
After a secondary dip to 7.81% in December 2024, a recovery trend is observed throughout 2025, with ROA climbing steadily to a high of 13.46% in December 2025. The final observation in March 2026 shows a moderation to 10.47%, indicating that the profitability ratio has largely returned to the historical levels seen prior to the 2023 volatility.